文献速递类风湿关节炎系统性红斑狼疮其他结缔组织病

嵌合抗原受体T细胞在慢性自身免疫性风湿病治疗中是否有用武之地?

Is There a Place for Chimeric Antigen Receptor-T Cells in the Treatment of Chronic Autoimmune Rheumatic Diseases?
PubMed 文献 · Arthritis Rheumatol · 2021-09-22

该综述讨论源自肿瘤学的嵌合抗原受体T(CAR-T)细胞技术能否转化并整合用于慢性自身免疫性风湿病治疗。文章介绍CAR-T技术细节及肿瘤血液学成果,回顾自身免疫病实验模型中CAR-T及其衍生构建体的初步数据,并聚焦类风湿关节炎、系统性红斑狼疮和系统性硬化症,探讨其是否可能比现有治疗更有效且不良事件更少。

要点

  • CAR-T细胞可靶向清除致病性B细胞或恢复免疫耐受。
  • 综述聚焦类风湿关节炎、系统性红斑狼疮和系统性硬化症。
  • 需评估CAR-T是否比现有治疗更有效且不良事件更少。

核心结论

  • 综述探讨CAR-T细胞技术转化用于慢性自身免疫性风湿病治疗的潜力,聚焦类风湿关节炎、系统性红斑狼疮和系统性硬化症,并讨论其是否可能比现有治疗更有效且不良事件更少。

研究设计与样本

  • 综述文章,基于CAR-T细胞技术在肿瘤血液学中的成功及自身免疫病实验模型中的初步数据,讨论其在慢性自身免疫性风湿病中的转化与整合。

主要发现

  • CAR-T细胞基于特异性靶向肿瘤抗原导致肿瘤细胞裂解和破坏,在B细胞恶性肿瘤治疗中已显示高效力。
  • 已开发新的CAR-T细胞衍生构建体,能够根除致病性B细胞或恢复免疫耐受。
  • 综述回顾了CAR-T细胞及其衍生构建体在自身免疫病实验模型中的初步数据。

临床怎么用

  • 综述讨论CAR-T细胞工程如何干预类风湿关节炎、系统性红斑狼疮和系统性硬化症的发病机制,并探讨其是否可能比当前治疗策略更有效且不良事件更少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor-T (CAR-T) cell therapy is based on specific targeting of tumor antigens, leading to lysis and destruction of tumor cells. The high potency of CAR-T cells in the management of B cell malignancies has been demonstrated. Following the success of this therapeutic strategy, new CAR-T cell-derived constructs that have the ability to eradicate pathogenic B cells or restore tolerance have been developed. The present review discusses how the knowledge and technology generated by the use of CAR-T cells may be translated and integrated into ongoing therapeutic strategies for autoimmune rheumatic diseases. To this end, we describe the details of CAR-T cell technology, as well as the meaningful achievements attained with the use of CAR-T cells in onco-hematology. In addition, we review the preliminary data obtained with CAR-T cells and their derivative constructs in experimental models of autoimmune diseases. Finally, we focus on how CAR-T cell engineering interferes with the pathogenesis of 3 chronic autoimmune rheumatic diseases-rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis-and discuss whether these constructs might yield greater efficacy and be associated with fewer adverse events compared to current treatment strategies.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Orvain C, Boulch M, Bousso P, et al. Is There a Place for Chimeric Antigen Receptor-T Cells in the Treatment of Chronic Autoimmune Rheumatic Diseases? Arthritis Rheumatol. 2021. PMID: 34042325. doi:10.1002/art.41812

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。